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Abstract
Background: The two inflammatory molecules, S100A8 and S100A9, form a heterodimer, calprotectin. Plasma calprotectin
levels are elevated in various inflammatory disorders. We hypothesized that plasma calprotectin levels would be increased
in subjects with low-grade systemic inflammation i.e. either obese subjects or subjects with type 2 diabetes.
Methodology/Principal Findings: Plasma calprotectin and skeletal muscle S100A8 mRNA levels were measured in a cohort
consisting of 199 subjects divided into four groups depending on presence or absence of type 2 diabetes (T2D), and
presence or absence of obesity. There was a significant interaction between obesity and T2D (p=0.012). Plasma calprotectin
was increased in obese relative to non-obese controls (p,0.0001), whereas it did not differ between obese and non-obese
patients with T2D (p=0.62). S100A8 mRNA levels in skeletal muscle were not influenced by obesity or T2D. Multivariate
regression analysis (adjusting for age, sex, smoking and HOMA2-IR) showed plasma calprotectin to be strongly associated
with BMI, even when further adjusted for fitness, CRP, TNF-a or neutrophil number.
Conclusions/Significance: Plasma calprotectin is a marker of obesity in individuals without type 2 diabetes.
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Introduction
Recently, two novel inflammatory molecules belonging to the
S100 protein family have been described, S100A8 (MRP8) and
S100A9 (MRP14)[1]. S100A8 and S100A9 form monovalent
homodimers and a heterodimer, known as calprotectin, in a
calcium-dependent manner. Both proteins are predominantly
expressed in myeloid cells depending on the stage of cell
differentiation and inflammatory status[1], however they have
also been found to be expressed in skeletal muscle[2]. Studies on
the regulation of S100A8 and S100A9 have shown that S100A9
seems to be ubiquitously expressed, while S100A8 can be induced
by a variety of stimulants such as lipopolysaccharide, interferon-c
and tumor necrosis factor-a[3]. S100A8 and S100A9 take part in
various processes of the innate immune response such as cell
adhesion, chemotaxis, and antimicrobial activity[1]. Phagocytes
expressing S100A8 and S100A9 and elevated plasma calprotectin
levels are found in a variety of chronic inflammatory conditions,
including rheumatoid arthritis, allograft rejections, and inflamma-
tory bowel and lung diseases[4]. Calprotectin has also been found
to be increased in plasma following exercise[5] and was recently
shown to be released from skeletal muscle tissue [6].
We hypothesized that plasma calprotectin and skeletal muscle
expression of S100A8 would be dysregulated in individuals with
systemic inflammation. As low-grade systemic inflammation is a
hallmark of both obesity and type 2 diabetes (T2D) we studied the
levels of plasma calprotectin and S100A8 skeletal muscle mRNA
levels using a cross-sectional case control design in which patients
with T2D and healthy controls were closely matched, not only




Ethics Statement. The participants received oral and written
information about the experimental procedures before giving their
written informed consent. The study was approved by the Ethical
Committee of Copenhagen and Frederiksberg Communities,
Denmark (KF 01-141/04), and performed according to the
Declaration of Helsinki.
Subjects
A cross-sectional design was employed. Participants (n = 199)
were divided into 4 groups according to BMI (above or below
30 kg/m2) and diagnosis of T2D. Subjects and protocol have
previously been described[7,8].
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Participants reported in the laboratory between 8 and 10 am
after an overnight fast. They did not take any medication in the
24 h preceding the examination and those with T2D did not take
oral antidiabetic medication for one week prior to examination
day. A general health examination was performed; blood samples
were drawn from an antecubital vein, a skeletal muscle biopsy was
obtained, an oral glucose tolerance test (OGTT), a fitness test was
performed, and subjects were scanned on a dual-energy X-ray
absorptiometry whole body scanner as previously described[7,8].
Blood analysis
Plasma calprotectin was measured using a commercial Enzyme
Linked Immunosorbent Assay (ELISA) kit (Hycult biotechnology,
Uden, NL). All measurements were performed in duplicate. Analysis of
other plasma parameters has been previously described[7,8].
Skeletal muscle tissue S100A8 mRNA
Skeletal muscle tissue biopsies were obtained from musculus
quadriceps and RNA isolated as previously described[8]. Following
cDNA synthesis (Applied Biosystems, Foster City, CA, USA), real-time
PCR was performed on an ABI 7900 Sequence Detection System
(Applied Biosystems) using pre-developed TaqMan assays (Applied
Biosystems) for S100A8 (Hs00374263_m1) and the endogenous
control, b-actin. The mRNA content of both targets and the
endogenous control, b-actin, was calculated from the cycle threshold
values using the standard curve method and relative expression of
S100A8 determined after normalisation to b-actin.
Statistics
All analyses were performed with SAS 9.1.2 (SAS Institute,
Cary, NC, USA. Plasma levels of triglycerides (TAG), glucose,
insulin, HOMA2-IR, HbA1c, IL-6, TNF-a, c-reactive protein
(CRP), plasma calprotectin, fitness (expressed as VO2max pr. kg fat
free mass), and S100A8 mRNA levels were log10-transformed to
approximate normal distribution. For these parameters results are
presented as geometric means with 95% confidence intervals (CIs).
For all other parameters results are presented as means with CIs.
Differences between glycaemia and obesity groups were tested in a
two-way analysis of variance (ANOVA) (PROC GLM with the
LSMEANS statement using Tukey HSD as post-hoc test).
Table 1. General characteristics of the study population and plasma calprotectin univariate and multivariate regression analysis.
Subject characteristics Regression analyses
Normal Glucose Tolerance Type 2 Diabetes Univariate Multivariate
Non-obese Obese Non-obese Obese RC p-value RC 95% CI p-value
n (male/female) 62 (42/20) 41 (28/13) 50 (38/12) 46 (34/12) – – – – –
Age (years) 56 (53–59) 48 (45–52) ** 58 (55–61) 58 (55–61) per unit 0.993 0.0019 – – –
Smoker (%) 17 (27%) 10 (24%) 11 (22%) 9 (20%) – – – – –
Fitness (VO2/kg/
FFM)
49.2 (45.8–52.9) 39.7 (36.4–43.2) *** 39.1 (35.9–42.7) 34.7 (31.7–37.9) ### pf10inc 0.713 0.0888 0.585 (0.379–0.903) 0.0159
WHR 0.91 (0.88–0.94) 0.99 (0.97–1.01) *** 0.96 (0.94–0.98) 1.00 (0.98–1.02) * # pf10inc 4.279 0.012 ns
BMI (kg/m
2) 25.7 (24.8–26.6) 36.7 (35.6–37.8) *** 26.6 (25.6–27.6) 35.5 (34.4–36.5) *** pf10inc 3.983 0.0001 3.184 (1.665–6.087) 0.0005
Total fat mass (kg) 20.5 (18.1–22.9) 44.3 (41.4–47.2) *** 22.9 (20.8–25.0) 37.5 (35.3–39.7) *** per unit 1.008 0.0001 1.007 (1.003–1.011) 0.0018
metabolicregulation
p-HDL (mM) 1.7 (1.5–1.8) 1.3 (1.2–1.4) *** 1.3 (1.2–1.4) 1.3 (1.2–1.4) per unit 0.784 0.0001 0.846 (0.740–0.846) 0.0138
p-LDL (mM) 3.6 (3.4–3.9) 3.3 (3.0–3.6) 2.9 (2.6–3.2) 3.0 (2.7–3.3) ### per unit 0.969 0.2062 ns
p-TAG (mM) 1.0 (0.9–1.2) 1.4 (1.2–1.7) ** 1.6 (1.3–2.0) 1.5 (1.2–1.9) pf10inc 1.269 0.0063 ns
p-Glucose (mM) 5.1 (5.0–5.2) 5.2 (5.1–5.4) 9.1 (8.2–10.1) 9.0 (8.0–10.1) ### pf10inc 1.184 0.2514 ns
p-Insulin (pM) 34.8 (29.8–40.6) 68.6 (56.9–82.6) *** 52.6 (43.3–64.0) 101 (82.5–124.0) *** ### pf10inc 1.278 0.0011 ns
HOMA2-IR 0.66 (0.56–0.76) 1.28 (1.07–1.54) *** 1.22 (1.0–1.50) 2.27 (1.83–2.81) *** ### pf10inc 1.266 0.0009 – – –
HbA1c (%) 5.5 (5.4–5.6) 5.6 (5.5–5.6) 7.3 (6.9–7.8) 6.9 (6.5–7.3) ### per unit 1.028 0.1086 ns
Inflammation
p-CRP (mg/l) 1.6 (1.3–1.9) 3.9 (3.1–5.0) *** 2.3 (1.8–3.0) 3.7 (2.9–4.8) ** pf10inc 1.445 0.0001 1.419 (1.249–1.612) 0.0001
p-TNFa (ng/l) 2.3 (2.2–2.4) 2.6 (2.4–2.8) ** 2.6 (2.4–2.8) 2.9 (2.6–3.1) ## pf10inc 1.720 0.0212 1.624 (1.015–2.597) 0.0431




2.91 (2.65–3.19) 3.54 (3.19–3.94) ** 3.76 (3.39–4.16) 3.88 (3.52–4.28) ### pf10inc 2.748 0.0001 2.702 (2.000–3.649) 0.0001
p-Calprotectin
(ng/ml)
58.7 (54.1–63.7) 81.2 (73.1–90.2) *** 68.0 (61.8–74.8) 73.8 (66.7–81.7) – – – – –
The study populationwas divided into 4 groups onthe basis of obesity (above or below30 kg/m
2)and diagnosisof type2 diabetes(T2D):Normal glucosetolerance(NGT)/Non-
obese, NGT/Obese, T2D/Non-obese andT2D/Obese. Data arepresented as numbersfor categoricalvariables and as means orgeometric means with 95%confidenceinterval(CI)
for continuous variables. #) Difference between glycemia group (NGT vs. T2D); #)p ,0.05, ##)p ,0.01, ###)p ,0.001. *) Difference between obesity groups within each
glycemia group. *) p,0.05,**) p,0.01,***) p,0.001.Forage,BMI,totalfatmass,p-HDL,p-TAG,p-IL-6,andp-calprotectin,therewasaninteractionbetweenglycemiagroupand
obesity.Hence,analyseswerestratifiedforglycemiagroupandonlycomparisonswithinglycemiagroupsareshown.Ascalprotectinlevelswerelog-transformed to approximate
a normaldistribution,regression coefficients(RC)and95% CIswereback-transformed,henceestimatingthefactorchange of calprotectinlevel attributable to a 1-unit change in
the predictor (per unit) or to a per factor-of-10 increase (pf10inc). The multivariate analysis was adjusted for age, sex, current smoking and HOMA2-IR.
doi:10.1371/journal.pone.0007419.t001
Calprotectin and Obesity
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performed with plasma calprotectin as the dependent variable and
parameters of obesity, inflammation, metabolism, and T2D as
explanatory variables. Results are presented as regression
coefficients with CIs. P,0.05 was considered significant.
Results
Plasma calprotectin is increased in obese subjects
General characteristics of the study population are shown in
Table 1. For plasma calprotectin, an interaction was found
between glycemia group and obesity in a two-way ANOVA
(p=0.012). Post-hoc tests showed that plasma calprotectin was
increased in obese relative to non-obese controls (p,0.0001),
whereas plasma calprotectin did not differ between obese and non-
obese patients with T2D (p=0.62) (Fig. 1A). The difference in
plasma calprotectin between obese and non-obese controls
persisted after adjusting for age and sex. Skeletal muscle S100A8
mRNA levels did not differ between groups (Fig. 1B).
Plasma calprotectin is a marker of BMI
Univariate- and multivariate regression analyses with plasma
calprotectin as the dependent variable are shown in table 1. In
univariate regression analysis, plasma calprotectin was positively
associated with BMI (Fig. 1C), waist-hip-ratio (WHR), total fat
mass, fasting insulin, HOMA2-IR, triglyceride, neutrophils and
CRP, and negatively associated with HDL, LDL, IL-6, TNFa,
and there was a trend for VO2max. In multiple regression analysis
(adjusting for age, sex, current smoking and HOMA2-IR), plasma
calprotectin was positively associated with BMI, total fat mass,
neutrophils, CRP, TNF-a, IL-6, and negatively associated with
HDL (table 1). When we further adjusted for VO2max, plasma
calprotectin was no longer associated with TNF-a (p=0.053).
Plasma calprotectin was associated with BMI after adjustment for
CRP (p=0.042), TNF-a (p=0.0007), and neutrophils (p=0.011),
but just failed to reach significance after adjustment for IL-6
(p=0.051).
Discussion
In the present study we demonstrated that obese subjects have
elevated plasma calprotectin compared to non-obese healthy
controls. In a multivariate regression analysis adjusted for age, sex,
smoking and fasting insulin we found a strong positive correlation
of plasma calprotectin with BMI, even when adjusting for CRP
and neutrophil number. Even though calprotectin has been found
to be expressed in and released from skeletal muscle [2,6], we
found no evidence of a dysregulation of one subunit of
calprotectin, S100A8, in obese or type 2 diabetic subjects on the
mRNA level, suggesting that the increased levels of calprotectin
seen in obese subjects are derived from another source than
skeletal muscle or that the level of S100A8 mRNA in skeletal
muscle in humans has too much individual variation compared
with plasma calprotectin. In support of this, we found no
correlation between plasma calprotectin and S100A8 mRNA
(data not shown). However, whether or not an increase in S100A8
mRNA is required for an increase in release of calprotectin from
skeletal muscle is currently unknown. One may speculate that the
increase in plasma IL-6 seen in healthy obese subjects compared to
lean subjects may be the driving force behind the increase in
plasma calprotectin in healthy obese subjects, as IL-6 is known to
upregulate S100A8 and S100A9 mRNA in skeletal muscle [6],
although an acute increase in systemic IL-6 levels did not increase
plasma calprotectin [6].
Figure 1. Plasma calprotectin and skeletal muscle mRNA levels
in humans. A) Plasma concentrations of calprotectin are shown for the
following four groups: Normal glucose tolerance (NGT)/Non-obese
(N=62), NGT/obese (N=41), type 2 diabetes (T2D)/non-obese (N=50),
T2D/obese (N=46). Data are expressed as geometric means; error bars
represent 95% confidence intervals (CIs). B) Skeletal muscle S100A8
mRNA are shown for the following four groups: NGT/Non-obese
(N=53), NGT/obese (N=37), T2D/non-obese (N=44), T2D/obese
(N=31). Data are expressed as geometric means; error bars represent
CIs. C) Log-transformed plasma concentrations of calprotectin, log(p-
calprotectin), and BMI, with circles and crosses depicting NGT and T2D
subjects, respectively. There was a significant correlation between
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have been found to be increased in type 1 diabetes patients and
have been suggested to be involved in the pathogenesis of type 1
diabetes[9]. However, in the current study, we found no
correlation between plasma calprotectin and parameters of glucose
homeostasis in the multivariate regression analysis, suggesting the
role of calprotectin in glucose homeostasis regulation is minimal.
Heterodimeric S100A8/S100A9, the form measued in this
study, but not the monomeric forms, has been shown to increase
detrimental effects caused by advanced end glycation products
(AGEs) and may therefore play a role in triggering atherosclerosis
in subjects associated with high levels of AGEs[10]. The negative
correlation between HDL cholesterol and plasma calprotectin may
thus indicate a role for calprotectin in the pathogenesis of
atherosclerosis. However, whether or not calprotectin directly
contributes to any pathological mechanisms in obese subjects is
presently unknown but warrants further investigation.
In conclusion, we found that high plasma calprotectin levels
were a marker of obesity independently of classical inflammation
markers such as CRP, TNF-a and circulating neutrophil number.
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